Skip to main content
Equibles
CGON logo

CGON · CG Oncology, Inc.

Track CGON — free

Use CGON with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$74.67 +0.34 (+0.46%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$6.62B
Shares
88.64M

CGON metrics

62 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$74.67
Market cap
$6.62B

Price action

19 metrics
Price change (1W)
+0.4%
Price change (30D)
-0.6%
Price change (3M)
+39.0%
Price change (6M)
+20.7%
Price change (YTD)
+79.8%
Price change (1Y)
+141.3%
Trailing year
Price change (5Y)
—
52-week high
$80.68
52-week low
$30.94
Change from 52-week high
-7.4%
Change from 52-week low
+141.3%
Annualized volatility
56.8%
Beta
1.1
RSI (14D)
48.6
Price vs SMA 50
+1.4%
Price vs SMA 200
+22.2%
Avg volume (3M)
955,278
Relative volume
0.3
Average dollar volume
$67.22M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.64M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
898.1×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1,062.7×
reciprocal yield 0.1%
P / book
6.4
reciprocal yield 15.5%
FCF yield
-2.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-4,056.2%
Trailing 12 months
Net margin
-3,602.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$252.62M
Net income (TTM)
−$224.38M
Trailing 12 months
Diluted EPS (TTM)
$-2.70
FCF margin
-2,879.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-23.57

Growth

11 metrics
Revenue growth YoY
+254.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.23M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-21.8%
Return on assets
-20.7%
Debt / equity
0.0
Current ratio
22.2
EBITDA (TTM)
−$249.66M
Free cash flow (TTM)
−$179.34M
Quick ratio
22.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.03B
Latest balance sheet
Cash & equivalents
$19.64M
Total assets
$1.09B
Total debt
$3.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$178.47M
Capital expenditures (TTM)
$876,000
R&D (TTM)
$156.23M
SG&A (TTM)
—
Stock compensation (TTM)
$35.33M
R&D / revenue
2,508.5%
Stock compensation / revenue
567.2%

Ownership (13F)

3 metrics
13F filers
236
13F filer change QoQ
-2
Institutional ownership
111.7%

Short interest

3 metrics
Short interest
12.7%
Latest settlement · 14.9 days to cover
Days to cover
14.9d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
$22.06M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1991792 CUSIP 156944100 13F (30d) 165 filings 165 filers Visit website Investor relations